A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).

MLA

Mezzanotte-Sharpe, Jessica, et al. “A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER2/Neu-Positive Metastatic Breast Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E1105).” Breast Cancer Research and Treatment, vol. 207, no. 2, Sept. 2024, pp. 275–82. EBSCOhost, https://doi.org/10.1007/s10549-024-07417-4.

APA

Mezzanotte-Sharpe, J., ONeill, A., Mayer, I. A., Arteaga, C. L., Yang, X. J., Wagner, L. I., Cella, D., Meropol, N. J., Alpaugh, R. K., Saphner, T. J., Swaney, R. E., Hoelzer, K. L., Gradishar, W. J., Abramson, V. G., Sundaram, P. K., Jilani, S. Z., Perez, E. A., Lin, N. U., Jahanzeb, M., … Reid, S. A. (2024). A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105). Breast Cancer Research and Treatment, 207(2), 275–282. https://doi.org/10.1007/s10549-024-07417-4

Chicago

Mezzanotte-Sharpe, Jessica, Anne ONeill, Ingrid A Mayer, Carlos L Arteaga, Ximing J Yang, Lynne I Wagner, David Cella, et al. 2024. “A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER2/Neu-Positive Metastatic Breast Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E1105).” Breast Cancer Research and Treatment 207 (2): 275–82. doi:10.1007/s10549-024-07417-4.